Bionano Historical Financial Ratios
| BNGO Stock | USD 3.12 0.18 5.45% |
Bionano Genomics is presently reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 34.43 or Days Sales Outstanding of 138 will help investors to properly organize and evaluate Bionano Genomics financial condition quickly.
Bionano |
About Bionano Financial Ratios Analysis
Bionano GenomicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Bionano Genomics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Bionano financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Bionano Genomics history.
Bionano Genomics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Bionano Genomics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Bionano Genomics sales, a figure that is much harder to manipulate than other Bionano Genomics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Bionano Genomics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Intangibles To Total Assets are very stable compared to the past year. As of the 27th of March 2025, Tangible Book Value Per Share is likely to grow to 1.72, while Price To Sales Ratio is likely to drop 91.68.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 1.74 | 2.56 | 2.94 | 3.27 | Days Of Inventory On Hand | 496.99 | 314.71 | 283.24 | 185.98 |
Bionano Genomics fundamentals Correlations
Click cells to compare fundamentals
Bionano Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bionano Genomics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 2.3K | 2.8K | 911.26 | 107.23 | 96.5 | 91.68 | |
| Ptb Ratio | 549.16 | 147.29 | 101.58 | 40.27 | 36.25 | 34.43 | |
| Days Sales Outstanding | 119.12 | 100.16 | 92.19 | 97.64 | 112.28 | 137.85 | |
| Book Value Per Share | 3.37 | 12.18 | 8.62 | 2.82 | 2.53 | 2.66 | |
| Free Cash Flow Yield | (0.001989) | (0.001478) | (0.005057) | (0.0328) | (0.0295) | (0.031) | |
| Operating Cash Flow Per Share | (3.68) | (2.6) | (4.32) | (3.67) | (3.3) | (3.46) | |
| Stock Based Compensation To Revenue | 0.18 | 0.54 | 0.81 | 0.42 | 0.38 | 0.22 | |
| Pb Ratio | 549.16 | 147.29 | 101.58 | 40.27 | 36.25 | 34.43 | |
| Ev To Sales | 2.3K | 2.8K | 911.49 | 108.93 | 98.04 | 93.13 | |
| Free Cash Flow Per Share | (3.68) | (2.65) | (4.43) | (3.72) | (3.34) | (3.51) | |
| Roic | (0.75) | (0.2) | (0.48) | (1.15) | (1.04) | (1.09) | |
| Inventory Turnover | 1.73 | 1.14 | 0.73 | 1.16 | 1.33 | 1.27 | |
| Net Income Per Share | (3.95) | (2.62) | (4.58) | (6.81) | (6.13) | (6.43) | |
| Days Of Inventory On Hand | 211.2 | 320.5 | 496.99 | 314.71 | 283.24 | 185.98 | |
| Payables Turnover | 1.96 | 1.45 | 1.74 | 2.56 | 2.94 | 3.27 | |
| Research And Ddevelopement To Revenue | 1.21 | 1.25 | 1.76 | 1.5 | 1.35 | 1.03 | |
| Cash Per Share | 3.69 | 9.05 | 3.91 | 1.96 | 2.25 | 2.14 | |
| Pocfratio | (502.83) | (690.35) | (202.98) | (30.94) | (35.58) | (37.36) | |
| Interest Coverage | (15.3) | (83.17) | (441.94) | (42.05) | (48.36) | (50.77) | |
| Pfcf Ratio | (502.83) | (676.61) | (197.75) | (30.52) | (35.1) | (36.86) | |
| Days Payables Outstanding | 186.61 | 250.87 | 209.31 | 142.76 | 128.48 | 121.19 | |
| Roe | (1.17) | (0.21) | (0.53) | (2.42) | (2.78) | (2.92) | |
| Ev To Operating Cash Flow | (502.25) | (690.16) | (203.03) | (31.43) | (36.14) | (37.95) | |
| Pe Ratio | (468.35) | (685.51) | (191.07) | (16.66) | (19.16) | (20.11) | |
| Return On Tangible Assets | (0.79) | (0.25) | (0.7) | (1.29) | (1.16) | (1.22) | |
| Ev To Free Cash Flow | (502.25) | (676.43) | (197.8) | (31.01) | (35.66) | (37.44) | |
| Earnings Yield | (0.002135) | (0.001459) | (0.005234) | (0.06) | (0.054) | (0.0567) | |
| Net Debt To E B I T D A | 0.6 | 0.19 | (0.0547) | (0.29) | (0.33) | (0.31) | |
| Current Ratio | 5.23 | 12.47 | 4.38 | 1.4 | 1.26 | 1.2 | |
| Tangible Book Value Per Share | 2.54 | 9.18 | 4.53 | 1.82 | 1.64 | 1.72 | |
| Receivables Turnover | 3.06 | 3.64 | 3.96 | 3.74 | 3.36 | 2.52 | |
| Shareholders Equity Per Share | 3.37 | 12.18 | 8.62 | 2.82 | 2.53 | 2.66 | |
| Debt To Equity | 5.54 | 0.47 | 0.0317 | 0.0468 | 0.83 | 0.74 |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.81 | VALN | Valneva SE ADR | PairCorr |
| 0.49 | DTIL | Precision BioSciences | PairCorr |
| 0.36 | EQ | Equillium | PairCorr |
| 0.33 | VERV | Verve Therapeutics | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (138.00) | Revenue Per Share | Quarterly Revenue Growth (0.35) | Return On Assets | Return On Equity |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.